Valeria Sanna

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease

Diego F. Calvisi, Federico Pinna, Sara Ladu et al. · Carcinogenesis · 2008 · 58 citations · Full text

Medicine, Oncology, Pathology +17

Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in breast cancer: a Sardinian preliminary case-control study

Paolo Castiglia, Valeria Sanna, Antonio Azara et al. · International Journal of Medical Sciences · 2019 · 40 citations · Full text

Medicine, Genetics, Molecular Genetics +16

Ras‐driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control

Diego F. Calvisi, Federico Pinna, Rossella Pellegrino et al. · International Journal of Cancer · 2008 · 39 citations · Full text

Medicine, Cancer Biology, Oncology +17

Mastectomy patterns, but not rates, are changing in the treatment of early breast cancer. Experience of a single European institution on 2315 consecutive patients

Alessandro Fancellu, Valeria Sanna, P Cottu et al. · The Breast · 2018 · 34 citations

Medicine, Oncology, Surgery +9